In lat­est AI tie-up, Sanofi part­ners with In­sil­i­co for six new tar­gets

Sanofi has inked a deal with AI drug com­pa­ny In­sil­i­co, mark­ing the Big Phar­ma’s third ma­jor AI drug deal this year.

The deal is for up to six undis­closed tar­gets, the duo an­nounced this morn­ing. Sanofi will dish out $21.5 mil­lion up­front, and down­stream mile­stones could add up to $1.2 bil­lion, ac­cord­ing to Sanofi.

“This col­lab­o­ra­tion will lever­age our com­ple­men­tary ca­pa­bil­i­ties, as well as the co-lo­ca­tion of our sci­en­tif­ic teams, to boost the drug dis­cov­ery ef­forts of the Sanofi In­sti­tute for Bio­med­ical Re­search (SIBR), Sanofi’s R&D cen­ter in Chi­na,” Sanofi’s head of Chi­na re­search Changchun Xi­ao said. In­sil­i­co is based out of Hong Kong and New York.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.